22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed outlook. While revenue growth and expansion plans are promising, financial challenges such as net loss and negative EBITDA persist. The market competition and consumer adoption challenges add uncertainty. The strategic focus on execution and cost management is positive, but the lack of a shareholder return plan and financial pressures balance the sentiment to a neutral stance.
Key Financial Performance
Net Revenue $4.1 million for Q1 2026, an increase of approximately 16.1% sequentially from $3.5 million in Q4 2025. The increase is attributed to the early indicators of commercial progress as distribution expands and product mix evolves.
Gross Loss $0.6 million for Q1 2026, compared to $0.8 million in Q4 2025. This improvement reflects better gross margin performance as revenue improved sequentially.
Operating Loss $3 million for Q1 2026, compared to $2.8 million in Q4 2025. The slight increase is due to ongoing investments in scaling revenue and managing costs.
Net Loss from Continuing Operations $3 million for Q1 2026, compared to $2.8 million in Q4 2025. This reflects the company's focus on scaling revenue and improving gross margin mix.
Adjusted EBITDA Negative $2.6 million for Q1 2026, compared to negative $2.4 million in Q4 2025. The decline is attributed to near-term profitability pressures while focusing on scaling revenue and managing costs.
Cash and Cash Equivalents $9.5 million at the end of Q1 2026. The company is managing liquidity carefully, aligning spending with commercial and regulatory priorities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VLN Cigarettes: The company is focused on the relaunch and initial shipments of VLN cigarettes, which are FDA-authorized and designed to help smokers reduce nicotine addiction. The product is positioned as a disruptive solution in the tobacco industry.
Retail Distribution Expansion: The company has secured distribution with the #3 and #2 purveyors of tobacco products in the U.S. and plans to expand to New York, New Jersey, Southern California, and the Southeast, targeting 5,000 retail outlets by the end of 2026.
Revenue Growth: Net revenue increased by 16.1% sequentially to $4.1 million in Q1 2026, indicating early commercial progress.
Cost Management: The company is addressing low-margin products, exiting unprofitable contracts, and managing costs to improve gross margins and profitability.
Consumer Marketing Investment: The company is hiring a new Vice President of Marketing to enhance consumer marketing efforts and drive awareness and adoption of VLN products.
Focus on Execution: The company is prioritizing execution, including expanding distribution, improving marketing campaigns, and advancing its regulatory and product pipeline.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The company faces significant competition from 'big tobacco' companies that are heavily investing in nicotine pouches and other nicotine solutions, which could limit the adoption of VLN cigarettes.
Consumer Adoption Challenges: The adoption of VLN cigarettes is still in its early stages, with some retail outlets experiencing slow sales. Consumer awareness and acceptance remain critical hurdles.
Financial Performance: The company reported a net loss of $3 million for Q1 2026, with profitability metrics under pressure. Gross losses and negative adjusted EBITDA indicate financial challenges.
Retail Expansion Risks: The company is in the process of expanding to 5,000 retail outlets by the end of 2026, but the success of this expansion is uncertain, with some stores showing slow sales.
Marketing and Operational Costs: The company plans to increase spending on marketing and operational headcount, which could strain financial resources if revenue growth does not meet expectations.
Regulatory and Market Headwinds: The company acknowledges potential headwinds from the market and regulatory challenges as it seeks to expand its VLN product line.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Market Expansion: The company plans to expand distribution of VLN products to New York, New Jersey, Southern California, and the Southeast in Q2 and Q3 2026, targeting approximately 200 outlets. By the end of 2026, the company aims to reach 5,000 retail outlets.
Consumer Marketing: The company is hiring a new Vice President of Marketing to lead consumer marketing efforts and drive awareness and adoption of VLN products among adult smokers. Investments in consumer marketing are expected to yield high returns.
Revenue Growth: The company anticipates measurable growth in revenue as distribution expands and consumer adoption increases, particularly in the back half of 2026.
Product Development: The company will continue to create new and innovative products using proprietary technology, including new strains of non-GMO, low nicotine tobacco.
Financial Focus: The company is addressing low or no margin products by adjusting pricing and exiting unprofitable contracts. It expects improvements in gross profits as the year progresses.
Operational Expansion: The company plans to add headcount in marketing and sales to support new opportunities and expand its platform.
Regulatory and Product Pipeline: The company is advancing its regulatory and product pipeline to support the VLN reduced nicotine platform and other opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA World
New
Pinnacle product
World Health
activity
adult smoker
awareness
cigarette fact
cigarette market
consumer adoption
consumer marketing
core
distribution outlet
effort
experience
form
improvement
launch
line
loss
nicotine
opportunity
pack
platform
problem
retailer
rollout
sale
side
smoking habit
store
tobacco
world
year
XXII Transcript
22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript
Unknown5-9
The earnings call reveals a mixed outlook. While revenue growth and expansion plans are promising, financial challenges such as net loss and negative EBITDA persist. The market competition and consumer adoption challenges add uncertainty. The strategic focus on execution and cost management is positive, but the lack of a shareholder return plan and financial pressures balance the sentiment to a neutral stance.
22nd Century Group, Inc. (XXII) Q4 2025 Earnings Call Prepared Remarks Transcript
Positive3-26
The earnings call highlighted a 25% YoY revenue increase and improved gross margins, indicating strong financial performance. Despite a net loss, the reduction in loss and improved EBITDA reflect positive cost management. No negative trends or concerns were raised in the Q&A. The lack of strategic updates or shareholder returns discussion is a minor drawback, but the financial improvements and optimistic outlook suggest a positive sentiment.
22nd Century Group, Inc. (XXII) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call reveals several challenges: declining net revenue, increased losses, and market adoption hurdles for VLN products. Despite optimistic profitability guidance, the company's transition to higher-margin products is slow and costly. Management's lack of clarity in the Q&A adds uncertainty, and the potential for regulatory and competitive pressures further complicates the outlook. Without clear strategies to overcome these obstacles, the stock is likely to face negative pressure over the next two weeks.
22nd Century Group, Inc. (XXII) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call highlights several concerns: declining net revenue, consistent net losses, and increased operating expenses despite efforts to transition to higher-margin products. The company faces profitability delays, regulatory challenges, and potential cash shortfalls, requiring additional fundraisings. Despite some positive steps like debt reduction and increased carton sales, the inability to provide clear guidance on cash sufficiency and breakeven timeline, along with competitive pressures, suggests a negative sentiment. Without a market cap, stock reaction may lean towards negative, potentially in the -2% to -8% range.
XXII Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
